Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.